Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Haemophilus influenzae | 28 | 2020 | 67 | 3.870 |
Why?
|
| Bacterial Proteins | 21 | 2020 | 491 | 2.040 |
Why?
|
| Haemophilus Infections | 13 | 2020 | 29 | 1.840 |
Why?
|
| Heme | 16 | 2013 | 91 | 1.620 |
Why?
|
| Carrier Proteins | 13 | 2009 | 252 | 1.290 |
Why?
|
| Genes, Bacterial | 8 | 2012 | 109 | 1.020 |
Why?
|
| Otitis Media | 9 | 2020 | 35 | 1.020 |
Why?
|
| Bacterial Outer Membrane Proteins | 10 | 2010 | 101 | 0.900 |
Why?
|
| Haptoglobins | 9 | 2011 | 22 | 0.840 |
Why?
|
| Lipoproteins | 3 | 2009 | 99 | 0.770 |
Why?
|
| Hemoglobins | 10 | 2013 | 118 | 0.700 |
Why?
|
| Chinchilla | 7 | 2020 | 32 | 0.690 |
Why?
|
| Bacteremia | 7 | 2013 | 81 | 0.660 |
Why?
|
| Operon | 5 | 2013 | 40 | 0.440 |
Why?
|
| Membrane Proteins | 2 | 2020 | 485 | 0.410 |
Why?
|
| Haemophilus influenzae type b | 2 | 2006 | 3 | 0.400 |
Why?
|
| Genetic Fitness | 1 | 2012 | 5 | 0.380 |
Why?
|
| Haemophilus | 1 | 2012 | 1 | 0.370 |
Why?
|
| Prostatic Neoplasms | 2 | 2025 | 282 | 0.370 |
Why?
|
| Virulence Factors | 2 | 2013 | 45 | 0.350 |
Why?
|
| Virulence | 7 | 2013 | 152 | 0.350 |
Why?
|
| Gene Expression Regulation, Bacterial | 8 | 2013 | 158 | 0.330 |
Why?
|
| HIV Infections | 2 | 2022 | 161 | 0.330 |
Why?
|
| Siderophores | 1 | 2010 | 5 | 0.330 |
Why?
|
| Rats | 10 | 2020 | 1587 | 0.330 |
Why?
|
| Hemopexin | 2 | 2007 | 4 | 0.320 |
Why?
|
| Mutation | 7 | 2012 | 864 | 0.300 |
Why?
|
| Catalase | 2 | 2012 | 49 | 0.300 |
Why?
|
| Molecular Sequence Data | 10 | 2012 | 1056 | 0.270 |
Why?
|
| Porphyrins | 1 | 2007 | 20 | 0.270 |
Why?
|
| Esterases | 1 | 2007 | 16 | 0.260 |
Why?
|
| Animals | 16 | 2020 | 10583 | 0.260 |
Why?
|
| NAD | 1 | 2007 | 104 | 0.260 |
Why?
|
| Iron | 6 | 2013 | 117 | 0.260 |
Why?
|
| Myoglobin | 1 | 2006 | 33 | 0.240 |
Why?
|
| Machine Learning | 1 | 2025 | 91 | 0.220 |
Why?
|
| Advisory Committees | 1 | 2024 | 33 | 0.220 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 93 | 0.220 |
Why?
|
| Disease Models, Animal | 6 | 2015 | 1494 | 0.210 |
Why?
|
| Humans | 18 | 2025 | 28585 | 0.200 |
Why?
|
| Haemophilus Vaccines | 2 | 2020 | 3 | 0.190 |
Why?
|
| Microsatellite Repeats | 2 | 1999 | 59 | 0.190 |
Why?
|
| Mouth Neoplasms | 1 | 2022 | 64 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 163 | 0.170 |
Why?
|
| Animals, Newborn | 4 | 2013 | 181 | 0.170 |
Why?
|
| Pregnancy | 4 | 2012 | 1219 | 0.170 |
Why?
|
| Mutagenesis | 2 | 1999 | 46 | 0.160 |
Why?
|
| Transcription, Genetic | 5 | 2013 | 404 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 554 | 0.150 |
Why?
|
| Multigene Family | 2 | 2010 | 51 | 0.140 |
Why?
|
| Regulon | 3 | 2013 | 18 | 0.140 |
Why?
|
| Burkholderia cepacia complex | 2 | 2006 | 4 | 0.120 |
Why?
|
| Amino Acid Sequence | 6 | 2006 | 695 | 0.120 |
Why?
|
| DNA, Bacterial | 5 | 2004 | 309 | 0.110 |
Why?
|
| Mutagenesis, Insertional | 2 | 2009 | 38 | 0.110 |
Why?
|
| RNA, Bacterial | 2 | 2012 | 65 | 0.110 |
Why?
|
| Host Factor 1 Protein | 1 | 2013 | 1 | 0.100 |
Why?
|
| Neoplasms | 1 | 2022 | 857 | 0.100 |
Why?
|
| Ear, Middle | 1 | 2013 | 40 | 0.100 |
Why?
|
| HIV | 2 | 2022 | 12 | 0.100 |
Why?
|
| Genetic Techniques | 1 | 2012 | 12 | 0.100 |
Why?
|
| Microbial Viability | 1 | 2012 | 29 | 0.100 |
Why?
|
| Culture Media | 3 | 2007 | 99 | 0.100 |
Why?
|
| Transcriptome | 1 | 2013 | 214 | 0.090 |
Why?
|
| Otitis Media with Effusion | 1 | 2012 | 15 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2012 | 7 | 0.090 |
Why?
|
| Male | 5 | 2025 | 13772 | 0.090 |
Why?
|
| Female | 7 | 2013 | 15472 | 0.090 |
Why?
|
| Term Birth | 1 | 2011 | 10 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2004 | 376 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 327 | 0.080 |
Why?
|
| Ferrichrome | 1 | 2010 | 2 | 0.080 |
Why?
|
| Base Sequence | 6 | 2004 | 588 | 0.080 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 128 | 0.080 |
Why?
|
| Infant, Premature | 1 | 2011 | 144 | 0.080 |
Why?
|
| Infant | 2 | 2012 | 1019 | 0.080 |
Why?
|
| Phylogeny | 1 | 2012 | 489 | 0.080 |
Why?
|
| Phenotype | 2 | 2012 | 682 | 0.070 |
Why?
|
| Middle Aged | 3 | 2025 | 7310 | 0.070 |
Why?
|
| Immune Sera | 2 | 2020 | 22 | 0.070 |
Why?
|
| Species Specificity | 3 | 2012 | 193 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 13 | 0.070 |
Why?
|
| Animals, Suckling | 1 | 2007 | 3 | 0.070 |
Why?
|
| Point Mutation | 1 | 2007 | 60 | 0.060 |
Why?
|
| Protease Inhibitors | 2 | 2022 | 40 | 0.060 |
Why?
|
| Cloning, Molecular | 4 | 1999 | 208 | 0.060 |
Why?
|
| Ferritins | 1 | 2006 | 27 | 0.060 |
Why?
|
| Cattle | 1 | 2007 | 388 | 0.060 |
Why?
|
| Hemagglutinins | 1 | 2006 | 2 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 82 | 0.060 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2006 | 31 | 0.060 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 15 | 0.060 |
Why?
|
| Kentucky | 1 | 2025 | 6 | 0.060 |
Why?
|
| Cytosol | 1 | 2005 | 49 | 0.060 |
Why?
|
| Child | 2 | 2010 | 2271 | 0.060 |
Why?
|
| Meningitis, Haemophilus | 1 | 2004 | 3 | 0.060 |
Why?
|
| Aged | 2 | 2025 | 5525 | 0.060 |
Why?
|
| Transformation, Bacterial | 1 | 2004 | 13 | 0.060 |
Why?
|
| Age Factors | 1 | 2007 | 734 | 0.060 |
Why?
|
| Community Participation | 1 | 2024 | 27 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 37 | 0.050 |
Why?
|
| Registries | 1 | 2025 | 393 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2006 | 269 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 80 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 302 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 490 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 194 | 0.040 |
Why?
|
| Oklahoma | 1 | 2024 | 1038 | 0.040 |
Why?
|
| Quality of Life | 1 | 2024 | 504 | 0.040 |
Why?
|
| Electrophoresis | 1 | 1999 | 13 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1999 | 27 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2020 | 103 | 0.040 |
Why?
|
| Enzymes | 1 | 1999 | 23 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2025 | 2612 | 0.040 |
Why?
|
| United States | 1 | 2024 | 2201 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 272 | 0.040 |
Why?
|
| Chloramphenicol Resistance | 1 | 1998 | 3 | 0.040 |
Why?
|
| Adult | 1 | 2010 | 7922 | 0.030 |
Why?
|
| Peptides | 1 | 2020 | 293 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2013 | 120 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1997 | 114 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2012 | 671 | 0.030 |
Why?
|
| Burkholderia Infections | 2 | 2006 | 4 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2004 | 270 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 2015 | 14 | 0.030 |
Why?
|
| Epitopes | 1 | 2015 | 185 | 0.030 |
Why?
|
| Computational Biology | 1 | 2015 | 156 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2015 | 452 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2013 | 6 | 0.030 |
Why?
|
| Peroxiredoxins | 1 | 2012 | 3 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2012 | 12 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 551 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 199 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 74 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2011 | 60 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 257 | 0.020 |
Why?
|
| Restriction Mapping | 2 | 1999 | 23 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 524 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 568 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 622 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2009 | 72 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 893 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1026 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 899 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1998 | 133 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 770 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1272 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 453 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 17 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2006 | 64 | 0.020 |
Why?
|
| Horses | 1 | 2006 | 35 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 415 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 782 | 0.020 |
Why?
|
| Hemagglutination Tests | 1 | 2006 | 6 | 0.020 |
Why?
|
| Burkholderia cepacia | 1 | 2006 | 5 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 242 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2006 | 34 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 77 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2006 | 112 | 0.010 |
Why?
|
| Environmental Microbiology | 1 | 2006 | 25 | 0.010 |
Why?
|
| Hemolysis | 1 | 2006 | 51 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 380 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1999 | 24 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 147 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 111 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1998 | 14 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 124 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 233 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 328 | 0.010 |
Why?
|
| Ribostamycin | 1 | 1998 | 1 | 0.010 |
Why?
|
| Spectinomycin | 1 | 1998 | 4 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1998 | 11 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1998 | 8 | 0.010 |
Why?
|
| Transferrin-Binding Proteins | 1 | 1997 | 1 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 92 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1998 | 87 | 0.010 |
Why?
|
| Iron-Binding Proteins | 1 | 1997 | 38 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 155 | 0.010 |
Why?
|
| Haemophilus ducreyi | 1 | 1996 | 1 | 0.010 |
Why?
|
| Protein Binding | 1 | 1998 | 664 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1996 | 39 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1996 | 74 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1997 | 1167 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1996 | 338 | 0.010 |
Why?
|